Skip to Content
Interactive Textbook on Clinical Symptom Research Logo


Home button

Trial Design: Pain Sections
Author Bio
Introduction
Placebo Effects
Single Dose Trials
Repeated Dose Trials
Explanatory Versus Pragmatic
Currently selected section: Dose-Response
Parallel Group Versus Crossover
Conclusion
 

 

Chapter 1: Clinical Trials of Pain Treatment: Dose-Response; Relative Potency; Combinations

 
           

Question 6.4.3

Sustained release drug
Morphine
Fentanyl
Ending dose, mean (sustained release med only)
200 mg/day
40 mcg/hr
Average pain, 100 mm VAS
42
43
Rescue doses/24 hrs
1.4
1.4

Note that patients were treated with morphine during the study screening period and during the first part of the morphine/fentanyl relative potency study. If patients develop tolerance to morphine that does not extend completely to other opioids, this "incomplete cross-tolerance" effect will tend to lower the required dose of the second opioid, fentanyl and make it appear more potent.

True               False

Page 41 of 52
      Previous Question